A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Owen A. O'Connor, Carol Portlock, Craig Moskowitz, David Straus, Paul Hamlin, Michael Stubblefield, Otila Dumetrescu, A. Dimitrios Colevas, Barbara Grant, Andrew Zelenetz

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalBritish Journal of Haematology
Volume143
Issue number2
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Keywords

  • Epothilones
  • Indolent non-Hodgkin lymphoma
  • Ixabepilone
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma'. Together they form a unique fingerprint.

  • Cite this